home.social

#eyleabiosimilar — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #eyleabiosimilar, aggregated by home.social.

  1. Yonhap Infomax News @[email protected] ·

    Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
    #YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #biosimilardivision #economics #financialmarkets #banking #securities #bonds
  2. Yonhap Infomax News @[email protected] ·

    Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
    #YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #samchundangpharm #eyleabiosimilar #q1earnings #operatingprofit #biosimilardivision
  3. Yonhap Infomax News @[email protected] ·

    Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
    #YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  4. Yonhap Infomax News @[email protected] ·

    Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
    #YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #samchundangpharm #eyleabiosimilar #q1earnings #operatingprofit #biosimilardivision
  5. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept
  6. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept
  7. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  8. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept